ArticleDiscover nano2025
Novel dual-targeting of biofilm formation and pyocyanin production in clinical Pseudomonas aeruginosa isolates using glutamine-modified thiosemicarbazone-conjugated ZnO nanoparticles.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is a highly adaptable opportunistic pathogen frequently associated with chronic and hard-to-treat infections, particularly in burn units and immunocompromised patients. Its intrinsic and acquired resistance to multiple antibiotics poses a major therapeutic challenge. While ZnO nanoparticles conjugated with thiosemicarbazone (TSC) have shown promise in general antimicrobial applications, their potential for simultaneously inhibiting biofilm formation and pyocyanin production-key virulence factors-in clinical P. aeruginosa strains remains unexplored. In this study, ZnO nanoparticles were synthesized via a hydrothermal route and conjugated with a glutamine-modified TSC ligand (ZnO@Glu-TSC) to enhance their antimicrobial efficacy. The nanoconjugate was comprehensively characterized using UV-Vis spectroscopy, X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDX). Functional evaluations were conducted against clinical isolates of P. aeruginosa, including minimum inhibitory concentration (MIC), fractional inhibitory concentration (FIC) index, biofilm inhibition, and pyocyanin suppression assays. ZnO@Glu-TSC nanoparticles exhibited a sharp UV-Vis absorption peak at 380 nm with a band gap of 3.26 eV, and XRD confirmed a hexagonal wurtzite structure with an average crystallite size of ~ 19.8 nm. The nanoconjugate demonstrated significantly enhanced antibacterial activity with MIC values ranging from 128 to 512 µg/mL and synergistic effects in 70% of clinical isolates (FIC ≤ 0.5, p < 0.01). Biofilm inhibition assays revealed an 80% reduction in biomass (OD values approaching those of the negative control), while pyocyanin production decreased by more than 75% at 512 µg/mL (p < 0.001). These results represent the first demonstration of ZnO@Glu-TSC's dual antivirulence action against clinical P. aeruginosa strains, underscoring its therapeutic promise as a potent, multi-targeted nanoantimicrobial candidate and warranting further development for translational nanomedicine applications in combating persistent infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.